Bli medlem
Bli medlem

Du är här


Navamedic ASA: Navamedic Q1 2014 results

Positive start of the year for Navamedic

Navamedic ASA (OSE: NAVA) today announced the Company's first quarter 2014
financial results. Navamedic repeated its sales record from the previous
quarter and increased revenues by 26 per cent compared to the first quarter
last year. EBITDA ended at NOK 2.0 million, compared to NOK 3.5 million last

However, Navamedic had a non-recurring extraordinary income of NOK 2.6 million
in last year's first quarter. Adjusted for this item, profitability from
operations in reality improved by NOK 1.1 million from last year's to this
year's first quarter. The first quarter EBITDA corresponds to a margin of 4.6
per cent, while the EBITDA margin last year (before the one-off income) was
2.6 per cent.

Navamedic showed a pre-tax profit of NOK 0.2 million in the first quarter of
2014, against NOK 1.9 million last year (including the one-off income).

"We saw a significant sales increase in all of our segments, while we also
work intensely to improve margins through e.g. product portfolio composition
and an active pricing policy. Navamedic will continue to show a sales growth.
However, our main focus going forward is on further improving profitability,"
Navamedic CEO Håkan Josephsson said.

For further information, please contact interim CEO Håkan Josephsson,
telephone +46 706 742 533 or CFO Bjørn Lindholt, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and
distributing more than 100 products in the Nordic and Benelux markets. The
Company operates three business areas; Pharma Products, Medical Nutrition and
Consumer Care based on its relationship with a number of pharmaceutical
product manufacturers. Navamedic is listed on the Oslo Stock Exchange
(ticker: NAVA).

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Navamedic ASA Q1 2014 Presentation
Navamedic ASA Q1 2014 Report


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Navamedic ASA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.